Vital Signs - Current Treatments for Alchoholism are Underutilized


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on November 26, 2007, provides a strategic overview of issues and advances in the development of medications for alcoholism. Additionally, a company spotlight is provided for Sirtris Pharmaceuticals, a biopharmaceutical company focused on developing treatments for diseases associated with aging and metabolic disorders. Reimbursement and regulatory news from the FDA is also provided for the week of November 12 - November 16, 2007.

Table of Contents

Vital Signs - Current Treatments for Alchoholism are Underutilized26 November 2007This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.